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Background:  Molecularly  targeted  agents  for non-small  cell  lung  cancer  (NSCLC)  can  provide  similar  efﬁ-
cacy  to chemotherapy  without  chemotherapy-associated  toxicities.  Combining  two  agents  with  different
modes  of  action  could  further  increase  the  efﬁcacy  of  these  therapies.  The  TASK  study  evaluated  the  efﬁ-
cacy  and  safety  of  the  epidermal  growth  factor  receptor  tyrosine  kinase  inhibitor  erlotinib  in combination
with  the  anti-angiogenic  agent  bevacizumab  as  ﬁrst-line  therapy  in  unselected,  advanced  non-squamous
NSCLC  patients.
Methods:  Patients  were  recruited  from  December  2007  to  September  2008.  Planned  sample  size  was
200  patients,  a total  of  124  patients  were  randomized.  Patients  were  randomized  using  a  minimization
algorithm  1:1  to receive  bevacizumab  (iv 15  mg/kg  day  1  of  each  21-day  cycle)  plus  chemotherapy  (gem-
citabine/cisplatin  or  carboplatin/paclitaxel  standard  doses,  4–6  cycles)  (BC  arm)  or bevacizumab  plus
erlotinib  (p.o.  150  mg/day;  BE arm)  until  disease  progression  or unacceptable  toxicity.  The  primary  end-
point  was  progression-free  survival  (PFS).  If  the  hazard  ratio  (HR)  of  PFS  for  BE  relative  to  BC was  above
1.25  at  the  pre-planned  interim  analysis  in favor  of  BC,  the  study  would  be  re-evaluated.  Secondary
endpoints  included  overall  survival,  response  rate and  safety.
Results: All randomized  patients  (n = 63  BE; n  = 61  BC)  were  evaluated  for  the  efﬁcacy  analyses.  At  the
updated  interim  analysis,  median  PFS  was  18.4  weeks  (95%  conﬁdence  interval  [CI]  17.0–25.1)  versus  25.0
weeks  (95%  CI  20.6–[not  reached])  for BE  versus  BC,  respectively  (HR  for  death  or  disease  progression,  BE
relative  to  BC,  2.05,  p = 0.0183).  The  incidence  of  death  was  19%  for  BE  treatment  compared  with  11.5% for
BC  treatment.  The  HR  for PFS  at the  updated  interim  analysis  was  above  1.25,  therefore  patients  on the
BE  arm  were  permitted  to change  arms  or  switch  to  another  drug  and  the  study  was  terminated.  Adverse
events  reported  were  as  expected.
 ClinicalTrials.gov identiﬁer: NCT00531960.               
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169-5002 ©  2013 The Authors. Published by Elsevier Ireland Ltd. 
ttp://dx.doi.org/10.1016/j.lungcan.2013.08.002
Open access under CC BY-NC-ND license. 
T. Ciuleanu et al. / Lung Cancer 82 (2013) 276– 281 277
Conclusions:  The  TASK  study  did  not  show  a beneﬁt  in  terms  of  PFS  for the  combination  of  erlotinib  with
bevacizumab in unselected  ﬁrst-line  advanced  non-squamous  NSCLC  compared  with  chemotherapy  plus
bevacizumab.
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. Introduction
Lung cancer is the leading cause of cancer-related death world-
ide [1], with recent statistics projecting 226,160 new cases in
he US alone in 2012 [2]. Current therapeutic options for ﬁrst-
ine non-small cell lung cancer (NSCLC) treatment are based on
latinum doublet chemotherapy, which provide overall survival
OS) of ∼8 months [3]. Advances in treatments include personal-
zed NSCLC therapies that focus on molecular targets to improve
utcomes and reduce cumulative toxicities seen with chemother-
pies. For patients with epidermal growth factor (EGFR) mutations,
GFR tyrosine-kinase inhibitors (TKIs) are recommended as ﬁrst-
ine therapy, for those with non-squamous disease without these
river mutations, agents such as pemetrexed and bevacizumab are
vailable [4].
Bevacizumab is a recombinant humanized monoclonal anti-
ody against vascular endothelial growth factor (VEGF). VEGF is
 key signaling molecule in developmental angiogenesis, promot-
ng survival of endothelial cells and new vessel growth [5]. Tumor
ependency on VEGF makes VEGF an attractive target for anti-
ancer treatments. The addition of bevacizumab to chemotherapy,
mproved OS with ﬁrst-line paclitaxel and carboplatin (12.3 months
or bevacizumab plus chemotherapy, hazard ratio [HR] 0.79, 95%
onﬁdence interval [CI]: 0.67–0.92; p = 0.003) [6]. The ﬁrst-line
VAiL study showed increased progression-free survival (PFS) with
he addition of bevacizumab to cisplatin–gemcitabine (HR 0.75, 95%
I: 0.64–0.87; p = 0.0003) [7]. In a phase IV trial bevacizumab-based
herapy resulted in median OS of 14.6 months (95% CI 13.8–15.3)
8].
Erlotinib is an EGFR TKI. EGFR is critical in pathways used in
ell proliferation and survival and increased expression is often
een in tumor cells [9]. Erlotinib demonstrated a signiﬁcant OS
eneﬁt versus placebo (HR 0.70, 95% CI: 0.58–0.85; p < 0.001) in
atients with advanced NSCLC who had failed prior chemother-
py in a randomized, double-blind trial (BR.21) [10,11]. This led
o approval of erlotinib for NSCLC patients who  have failed at
east one prior chemotherapy regimen. Erlotinib was  also shown
o be effective in the post-marketing single-arm phase IV TRUST
tudy [12]. Additionally, data for erlotinib [13,14] have resulted
n its approval as ﬁrst-line therapy for EGFR mutation-positive
SCLC, and as maintenance treatment in unselected NSCLC patients
fter ﬁrst-line platinum-based chemotherapy [15]. Similar ben-
ﬁts have not been observed with ﬁrst-line treatment of NSCLC
ith TKIs in populations not selected by EGFR mutation. In a
tudy comparing ﬁrst-line erlotinib with chemotherapy in patients
ith advanced NSCLC not selected for EGFR mutations, median
S was 6.5 months for erlotinib and 9.7 months for chemother-
py (HR 1.73, 95% CI: 1.09–2.73, p = 0.018) [16]. The TORCH study
howed median OS of 8.7 months for ﬁrst-line erlotinib versus
1.6 months for chemotherapy in EGFR unselected patients [17]. In
he non-inferiority studies iPASS and First-SIGNAL, comparing the
KI geﬁtinib with chemotherapy, progression-free survival (PFS)
nd OS in populations not selected by EGFR mutation were similar
18,19].
Combining bevacizumab with erlotinib has shown promising
ctivity in second-line treatment [20,21]. Preclinical and clinical
rial data suggest the combination of erlotinib and bevacizumab
as similar efﬁcacy to standard platinum-based chemotherapy plus
evacizumab (median PFS of 6.2–6.3 months) but with reduceduthors. Published by Elsevier Ireland Ltd. 
toxicity  [22,23]. The SAKK 19/05 study suggested that bevacizumab
and erlotinib ﬁrst-line treatment was feasible with acceptable tox-
icity and activity (PFS 4.1 months, OS 14.1 months) [24]. However,
in another study the ﬁrst-line combination of bevacizumab and
erlotinib resulted in a non-progression rate of 75%, PFS of 3.8
months (95% CI: 2.3–5.4) and OS of 6.9 months (95% CI: 5.5–8.4)
[25]. These data warranted further investigation of the optimal
setting for a bevacizumab and erlotinib combination regimen.
The  BO20571 (TASK) study evaluated the efﬁcacy and safety of
bevacizumab in combination with either erlotinib or chemotherapy
as ﬁrst-line therapy in advanced NSCLC (ClinicalTrials.gov identi-
ﬁer: NCT00531960).
2.  Methods
2.1. Patients
TASK was  a phase II, open-label, multicenter, randomized, two-
arm, ﬁrst-line study in patients with advanced non-squamous
NSCLC. The trial was approved by the medical ethics commit-
tee of each participating center and was  performed in accordance
with the Declaration of Helsinki and Guidelines for Good Clinical
Practice. All patients provided written informed consent prior to
any study-related procedure. The study had a planned sample size
of 200 patients.
Patients aged ≥18 years were eligible if they had advanced or
recurrent, untreated, stage IIIB/IV NSCLC, with Eastern Co-operative
Oncology Group (ECOG) performance status (PS) 0–1. Formalin-
ﬁxed parafﬁn-embedded primary tumor samples were mandatory.
Patients were excluded if they had squamous cell histology, cen-
tral pulmonary lesions, central nervous system metastases, history
of grade ≥2 hemoptysis, received prior treatment with an EGFR
inhibitor, chemotherapy or anti-angiogenic therapy, received prior
radiotherapy or surgery within 4 weeks, signiﬁcant ophthalmic
abnormalities, or had abnormal blood cell count, liver function tests
or creatinine clearance. Patients receiving anticoagulants, acetylic
salicylic acid, dipyramidole, ticlopidine, clopidogrel or cilostazol at
baseline were also excluded.
2.2.  Study treatment
Patients  were randomized to receive erlotinib (p.o. 150 mg/day)
plus bevacizumab (i.v. 15 mg/kg, day 1 of each 21-day cycle) until
disease progression or unacceptable toxicity (BE arm) or 4–6 cycles
of gemcitabine/cisplatin (gemcitabine 1250 mg/m2 days 1 and 8
and cisplatin 80 mg/m2 on day 1 of each 21-day cycle) or car-
boplatin/paclitaxel (carboplatin AUC 6 on day 1 and paclitaxel
200 mg/m2 on day 1 of each 21-day cycle), plus bevacizumab (i.v.
15 mg/kg on day 1 of each 21-day cycle; BC arm). Following 4–6
cycles of chemotherapy, single-agent bevacizumab was  continued
until disease progression or unacceptable toxicity. Patients were
centrally randomized and allocated drug packs via an Interactive
Voice Response System.
2.3.  Efﬁcacy and safety analyses
Open access under CC BY-NC-ND license. The primary endpoint was assessment of the HR for PFS with BE
relative to BC. Secondary endpoints included OS, objective response
rate (ORR) and safety proﬁle. A pre-speciﬁed exploratory biomarker
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Table 1
Baseline demographics in the overall population.
Characteristic BC arm (n = 61) BE arm (n = 63)
Age, years
Mean (range) 58 (39–78) 61 (30–77)
Gender,  n (%)
Male  36 (59) 37 (59)
Female  25 (41) 26 (41)
ECOG  PS, n (%)
0  20 (33) 28 (44)
1  41 (67) 35 (56)
Smoking  status, n (%)
Smoker  24 (39) 22 (35)
Non-smoker 23 (38) 21 (33)
Former  smoker 14 (23) 20 (32)
Histology,  n (%)
Adenocarcinoma 53 (88) 56 (89)
Other  7 (12) 7 (11)
Disease  stage, n (%)
Unresectable  stage IIIB 15 (25) 10 (16)
Stage  IV 46  (75) 53 (84)ig. 1. Summary of patient disposition. AE, adverse event; BC, bevacizumab plus
hemotherapy; BE, bevacizumab plus erlotinib
nalysis was planned for patients with immunohistochemistry
GFR  protein expression-positive tumors, patients with high EGFR
ene copy number measured by ﬂuorescence in situ hybridiza-
ion, and patients with EGFR mutations. Due to early termination of
he study only PFS/OS correlation with EGFR mutation status was
ssessed.
Tumor response was assessed at 6 weeks according to Response
valuation Criteria in Solid Tumors (RECIST) version 1.0, then every
 weeks until week 24, following which tumor response was mea-
ured every 12 weeks. A physical examination and vital signs were
ssessed at baseline and on day 1 of every cycle (cycle 2 until with-
rawal). Adverse events (AEs) were assessed at each clinical visit
nd followed until 6 months after the last drug administration.
.4.  Statistical analyses
Based  on the E4599 trial results [6], BC-treated patients were
xpected to have a median PFS of ∼6.4 months. Approximately
00 patients were therefore needed to give an adequate number of
atients [26,27]. Assuming a PFS of 6.4 months (27.8 weeks) in each
rm, 141 events were estimated for 200 patients, giving a standard
rror for the log HR of ∼0.168. If treatment arms had equivalent
fﬁcacy the 95% CI of an HR of 1 would be 0.72–1.39.
The full analysis set included all randomized patients (n = 63
E; n = 61 BC), analyzed according to the therapy to which they
ere randomized. The safety population included all patients who
eceived ≥1 dose of study drug and completed ≥1 safety follow-up.
PFS was deﬁned as time between randomization and ﬁrst occur-
ence of disease progression or death, whichever occurred ﬁrst.
FS was analyzed according to the investigators’ assessments using
ECIST plus clinical progression criteria.
A pre-planned interim analysis was undertaken on 17
eptember 2008. This analysis was to assess whether to stop or
valuate the study if efﬁcacy in the BE arm was worse than the
C arm. If the HR was greater than 1.25, indicating BC treatment
as better than BE, the study would be re-evaluated. An updated
nalysis was performed on 6 January 2009 in order to increase the
ollow-up period of the randomized patients. The ﬁnal analysis was
n 9 September 2011.
.  Results.1. Patient population
From  31 December 2007 to 17 September 2008, 124 patients
ere randomized (BE, n = 63; BC, n = 61; Fig. 1); 14 patients wereBC, bevacizumab plus chemotherapy; BE, bevacizumab plus erlotinib; ECOG, Eastern
Cooperative Oncology Group; PS, performance status.
withdrawn from trial treatment for safety reasons (8 BC and 6 BE).
After results of the updated interim analysis were communicated,
10 patients were withdrawn due to administrative reasons in the
BE arm (5 patients switched to commercially available erlotinib,
2 patients were withdrawn due to investigator decision and 3
patients were withdrawn due to study end). In the BC arm 4 patients
switched to commercially available erlotinib.
At the pre-planned interim analysis (data cut-off 17 September
2008) there were no post-baseline PFS assessments for 20 BE
patients and 18 BC patients due to <6 weeks between random-
ization and data cut-off. A further 12 patients in each arm were
censored after randomization but before week 6. The HR for
PFS for BE relative to BC treatment was above the predeﬁned
threshold of 1.25 (HR 2.17, 95% CI: 0.88–5.34). To account for
the patients with no PFS events or insufﬁcient time between
randomization and cut-off to be accurately assessed, an updated
interim analysis (data cut-off 6 January 2009) was performed.
Recruitment was  kept on hold but enrolled patients contin-
ued treatment. The HR for PFS at the updated interim analysis
was above the pre-deﬁned value of 1.25 (HR 2.05, 95% CI:
1.11–3.77; p = 0.0183). Therefore recruitment was  stopped perma-
nently.
Baseline demographics and patient characteristics for the
intent-to-treat population are shown in Table 1. Both arms had a
higher proportion of males than females, and more patients with
ECOG PS 1 compared with PS 0. Most patients had adenocarcinoma
histology and most had stage IV disease.
3.2. Efﬁcacy outcomes
By  the ﬁnal analysis (9 September 2011) all patients had been
withdrawn from trial treatment, therefore ﬁnal analysis data are
not available for some endpoints. All presented results are from
the updated interim analysis (6 January 2009) unless otherwise
stated.
At the updated analysis, the risk of disease progression or
death was  signiﬁcantly higher with BE compared with BC (HR
2.05, 95% CI: 1.11–3.77; log rank p = 0.0183). A total of 30 events
in the BE arm (47.6%) and 16 events in the BC arm (26.2%)
were observed. Median PFS was  18.4 weeks (95% CI: 17.0–25.1)
with BE and 25.0 weeks (95% CI: 20.6–[not reached]) with BC.
The p value of 0.0183 indicated a signiﬁcant difference in PFS
in favor of BC (Fig. 2). No subgroups particularly beneﬁted from
the BE combination. In the subgroup analysis by EGFR mutation
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Table 2
HR  and 95% CI for PFS by EGFR subgroups.
Subgroup BC arm (n = 61) BE arm (n = 63) HR 95% CI
Patients per group No. events Median PFS, weeks Patients per group No. events Median PFS, weeks
EGFR IHC positive 26 5 NR 29 15 18 3.03 1.10–8.36
EGFR  IHC negative 14 5 24.1 11 4 NR 0.96 0.26–3.59
EGFR  FISH positive 23 6 NR 28 12 23.4 1.21 0.44–3.33
EGFR  FISH negative 13 5 24.1 11 7 12.1 2.62 0.75–9.10
EGFR  mutation positive 11 0 NR 13 2 NR >100 0.00–NA
EGFR  wild type 29 11 24.1 30 19 16.0 2.07 0.98–4.40
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GFR mutation status data was not available for all patients.
tatus (n = 13 BE, n = 11 BC), there were two PFS events in the
E arm and no PFS events in the BC arm for patients with
GFR mutation-positive tumors (Table 2). At the ﬁnal analysis 9
atients (69.2%) with an EGFR-activating mutation had a PFS event
n the BE arm and 8 patients (72.7%) had an event in the BC
rm.
At the updated interim analysis, the incidence of death (mainly
ue to disease progression, PD) was higher with BE compared with
C (n = 12 [19%; 5 PD, 1 AE, 1 unknown] versus n = 7 [11.5%; 10
D, 2 AE], respectively), although no signiﬁcant difference was
een (HR 1.63; 95% CI: 0.64–4.15, log rank p = 0.2994). Median OS
as not reached in either arm (Kaplan–Meier curves did not drop
elow 50%). At the ﬁnal analysis, median OS was  16.4 months for
E and not reached for BC (HR 1.24, 95% CI: 0.75–2.05; log rank
 = 0.4063); the incidence of death was higher with BE compared
ith BC (n = 33 [52.4%] versus n = 28 [45.9%], respectively). In the
ubgroup of patients with EGFR mutations, there was one death
due to pneumonia) in the BE group and none in the BC group by
he ﬁnal analysis. Second-line or further therapy was received by
6% of BC patients (most common was TKI, 38%) and 49% of BE
atients (most common was antimetabolites, 24%).
The  ORR was 23.8% (n = 15) with BE (95% CI: 14.0–36.2) com-
ared with 34.4% with BC (n = 21) (95% CI: 22.7–47.7; chi-squared
 = 0.19) at the updated analysis (all partial responses). The esti-
ated odds ratio for response with BE versus BC was  0.60 (95%
I: 0.27–1.30) indicating a higher response with BC. No patient
chieved a complete response in either arm. The rate of stable dis-
ase was similar in the BE and BC arms (47.6% [n = 30] versus 49.2%
n = 30], respectively). Patients not achieving a response or stable
isease were n = 13 for BE and n = 5 for BC.
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3.3. Safety and tolerability
AEs  in the safety population were reported by 84.1% of patients
in the BE arm and 82.0% in the BC arm (Table 3), with no unexpected
AEs reported. A higher proportion of BE-treated patients expe-
rienced events that were considered related to study treatment
compared with BC-treated patients (81.0% versus 75.4%, respec-
tively; study treatment includes chemotherapy or bevacizumab
or erlotinib). More BC-treated patients experienced a serious AE
(29.5% versus 23.8%) or a related serious AE (24.6% versus 11.1%)
than BE-treated patients, however, there were more deaths during
the treatment period with BE (8 patients, 12.7%) compared with
BC (4 patients, 6.6%), mostly due to disease progression. The higher
number of serious AEs in the BC arm was  due mainly to abnormal-
ities in blood parameters.
The  most frequently reported AEs were gastrointestinal events
(Table 4); more BC-treated patients reported events in this class
(67.2% versus 50.8% in the BE arm). A higher proportion of BE-
treated patients reported diarrhea (31.7% versus 19.7% in the BC
arm), while a higher proportion of BC-treated patients reported
vomiting (29.5% versus 7.9% in the BE arm). A higher incidence
of abnormal blood parameters (neutropenia, anemia, thrombocy-
topenia and leucopoenia) was seen in the BC arm and there were
more cases of epistaxis. Consistent with the known safety proﬁle
for erlotinib, more events of rash and pruritus were reported in the
BE arm. No cases of interstitial lung disease were reported during
the study.
At  the updated interim analysis, two patients from each treat-
ment arm had withdrawn due to AEs considered related to study
treatment. From the BC arm, one patient with reversible posterior
leukoencephalopathy syndrome and one patient with thrombo-
sis withdrew. From the BE arm two patients with pulmonary
embolisms withdrew; one patient suffering an ischemic stroke
also withdrew, however, this was not considered related to study
Table 3
Summary of AEs in the overall population.
n (%) BC arm (n = 61) BE arm (n = 63)
Patients with at least one AE 50 (82.0) 53 (84.1)
Deaths  4 (6.6) 8 (12.7)
Study  withdrawals due to an AE 2 (3.3) 3 (4.8)
Patients  with at least one:
AE  leading to death 2 (3.3) 2 (3.2)
Serious  AE 18 (29.5) 15 (23.8)
Treatment-related serious AE 15 (24.6) 7 (11.1)
AE  leading to withdrawal 4 (6.6) 4  (6.3)
AE  leading to dose modiﬁcation 27 (44.3) 21 (33.3)
Treatment-related AE 46 (75.4) 51 (81.0)
Related  AE leading to withdrawal 3 (4.9) 2 (3.2)
Severe  AE 28 (45.9) 22 (34.9)
AE, adverse event; BC, bevacizumab plus chemotherapy; BE, bevacizumab plus
erlotinib.
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Table  4
Summary of AEs with an incidence rate >5% in the overall study population.
Body system/AE, n (%) BC arm (n = 61) BE arm (n = 63)
Gastrointestinal disorders
Nausea  31 (50.8) 10 (15.9)
Diarrhea  12 (19.7) 20 (31.7)
Vomiting 18 (29.5) 5 (7.9)
Constipation 7 (11.5) 4 (6.3)
Stomatitis 4 (6.6) 7 (11.1)
Abdominal pain 3 (4.9) 5 (7.9)
Dyspepsia 3 (4.9) 4 (6.3)
Abdominal pain upper 4 (6.6) 1 (1.6)
Skin  and subcutaneous tissue disorders
Rash 6 (9.8) 31 (49.2)
Alopecia  12 (19.7) 7 (11.1)
Pruritus  1 (1.6) 9 (14.3)
Dry  skin – 4 (6.3)
Respiratory and thoracic disorders
Cough 4 (6.6) 11 (17.5)
Dyspnea  6 (9.8) 9 (14.3)
Epistaxis 12 (19.7) 1 (1.6)
Hemoptysis 5 (8.2) 4 (6.3)
Dysphonia 2 (3.3) 5 (7.9)
Oropharyngeal pain 1 (1.6) 6 (9.5)
Blood  system disorders
Neutropenia  21 (34.4) –
Anemia  12 (19.7) 1 (1.6)
Thrombocytopenia 12 (19.7) 1 (1.6)
Leucopenia 11 (18.0) –
General  disorders
Asthenia 9 (14.8) 5 (7.9)
Fatigue  9 (14.8) 5 (7.9)
Mucosal  inﬂammation 3 (4.9) 5 (7.9)
Vascular  disorders
Hypertension 7 (11.5) 9 (14.3)
Nervous  systems disorders
Headache  3 (4.9) 6 (9.5)
Neuropathy 6 (9.8) –
Infections
Paronychia 1 (1.6) 6 (9.5)
Upper  respiratory tract infection 1 (1.6) 5 (7.9)
Musculoskeletal disorders
Myalgia  6 (9.8) 2 (3.2)
Back  pain 4 (6.6) –
Psychiatric disorders
Insomnia  4 (6.6) 3 (4.8)
Renal  disorders
Proteinuria 2 (3.3) 4 (6.3)
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received payment for consultancy from Roche and Pﬁzer. Dr. G.E, adverse event; BC, bevacizumab plus chemotherapy; BE, bevacizumab plus
rlotinib.
reatment. The majority of deaths were due to progression, occur-
ing during safety follow-up.
.  Discussion
This study evaluated efﬁcacy and safety of erlotinib plus
evacizumab compared with bevacizumab plus chemotherapy as
rst-line treatment in patients unselected for EGFR mutation sta-
us with advanced non-squamous NSCLC. At the interim analysis,
he HR for death or disease progression (2.17) was above the pre-
eﬁned threshold of 1.25. An updated analysis was undertaken to
llow longer follow-up as some patients could not be evaluated due
o insufﬁcient follow-up time from randomization. The updated
nalysis showed that the BE combination did not produce a PFS
eneﬁt compared with BC therapy (HR 2.05); therefore the primary
ndpoint was not met. Subgroup ﬁndings, including patients with
GFR mutation-positive disease were consistent with those for the
verall randomized population. One reason that no beneﬁt with
rlotinib treatment was seen in the EGFR mutation-positive group
ay be due to the low patient numbers in this subgroup. As well as
 shorter PFS beneﬁt, a higher incidence of death was reported iner 82 (2013) 276– 281
the  BE arm than the BC arm (interim analysis HR 1.63; ﬁnal analysis
HR 1.24).
As  the results of the updated interim analysis were com-
municated to investigators with guidance that patients could
discontinue BE treatment or switch to an alternative treatment,
the ﬁnal analysis data may  be subject to bias, and must be inter-
preted with caution. The results of the updated interim analysis are
considered the most valid assessment of the BE treatment combi-
nation in this instance. The Kaplan–Meier curves for PFS are clearly
separated at the updated interim analysis.
No new safety ﬁndings were identiﬁed for either combination
in this study. As expected, a higher proportion of patients in the BE
arm reported diarrhea than in the BC arm, while a higher incidence
of blood disorders were reported in the BC arm.
Other trials have investigated the combination of bevacizumab
and erlotinib in different settings for the treatment of advanced
NSCLC. Herbst et al. investigated bevacizumab plus erlotinib or
chemotherapy versus chemotherapy plus placebo for the treatment
of recurrent/refractory NSCLC (n = 120) [21]. Median PFS was  4.4
months (HR 0.72 [95% CI: 0.42–1.23]) for BE versus 4.8 months
(HR 0.66 [95% CI: 0.38–1.16]) for BC. These data suggested that
the BE combination had similar efﬁcacy to chemotherapy in a
second-line setting. The BRAIN study of BE in second-line treatment
of NSCLC patients with asymptomatic brain metastases (n = 24)
demonstrated a median PFS of 6.3 months (95% CI: 2.5–8.4) and
a 6-month PFS rate of 58% [23].
INNOVATIONS investigated ﬁrst-line BE in NSCLC and also
showed no beneﬁt with the BE combination compared with BC reg-
imen. Median PFS was 3.5 months for BE versus 7.7 months for BC.
OS was  12.6 months versus 16.3 months for BE versus BC [28]. The
ﬁrst-line SAKK 19/05 study showed a BE combination resulted in
PFS of 4.1 months and OS of 14.1 [24].
In previous studies investigating the use of the single-agent
TKIs for the treatment of ﬁrst-line NSCLC, the results in unselected
patients were not encouraging [16,18,19,29]. While the combina-
tion of bevacizumab and erlotinib showed promise in second-line
treatment, the TASK and INNOVATIONS studies suggest that the
addition of bevacizumab to ﬁrst-line erlotinib does not improve
outcomes for unselected patients with NSCLC. A recent editorial
highlighted that combining more agents is not necessarily bet-
ter when designing clinical trials and using agents with different
modes of action should only be done when preclinical data support
the combination in that particular setting [30].
5. Conclusions
This study did not show a PFS beneﬁt for the BE combination
in ﬁrst-line advanced NSCLC compared with BC. Subgroup ﬁndings
were consistent with the overall population. The premature termi-
nation of study treatment in the BE arm does not allow for a reliable
assessment of efﬁcacy in the smaller subgroups of patients, includ-
ing those with EGFR mutations. Based on these ﬁndings the erlotinib
plus bevacizumab combination is not currently recommended for
ﬁrst-line NSCLC.
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